# Cannabis oil modulates liver alterations and endocannabinoid system changes in a female rat model of diet-induced MASLD

**Authors:** Valentina Degrave, Michelle Berenice Vega Joubert, Paola Ingaramo, Daniela Sedan, Darío Andrinolo, Tomas M. Mac Loughlin, María Eugenia D’Alessandro, María Eugenia Oliva

PMC · DOI: 10.3389/fnut.2026.1770150 · Frontiers in Nutrition · 2026-03-10

## TL;DR

Cannabis oil improves liver health and balances the endocannabinoid system in female rats with diet-induced liver disease.

## Contribution

The study explores cannabis oil effects on liver disease in a female rat model, an area previously understudied.

## Key findings

- Cannabis oil reduced liver steatosis and fibrosis markers in female rats.
- It normalized endocannabinoid levels and reduced oxidative stress.
- Cannabis oil improved lipid metabolism and modulated key inflammatory pathways.

## Abstract

Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to alterations in liver lipid metabolism, oxidative stress, fibrosis, and dysregulation of the endocannabinoid system (ECS). Although increasing evidence supports a role for cannabinoids in metabolic disorders, most preclinical studies have been conducted in male models, leaving female-specific responses largely unexplored.

This study evaluated the effects of oral administration of a full-spectrum cannabis oil (CBD:THC 2:1) on MASLD-related alterations and ECS regulation in female Wistar rats fed a sucrose-rich diet (SRD). Rats were assigned to reference diet (RD), SRD, or SRD plus cannabis oil (1 mg/kg/day) for 3 weeks.

SRD-fed rats developed liver steatosis and increased NAFLD activity score (NAS), accompanied by enhanced de novo lipogenesis, reduced mitochondrial fatty acid oxidation, increased oxidative stress, early fibrotic changes, and ECS overactivation. Cannabis oil administration improved liver lipid metabolism, reduced NAS and fibrosis markers, attenuated lipid peroxidation and oxidative stress, increased NrF2 and decreased NF-κB p65 expression, and normalized hepatic CB1 expression and circulating endocannabinoid levels.

These findings demonstrate that full-spectrum cannabis oil is associated with improved MASLD-related outcomes and modulation of ECS tone in a female-specific model of diet-induced metabolic liver disease.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], CNR1 (cannabinoid receptor 1) [NCBI Gene 1268]
- **Chemicals:** CBD (PubChem CID 644019), THC (PubChem CID 16078)
- **Diseases:** MASLD (MONDO:0013209), NAFLD (MONDO:0013209)

## Full-text entities

- **Genes:** Cnr1 (cannabinoid receptor 1) [NCBI Gene 25248] {aka CB-R, CB1, CB1R, SKR6R}, Nfe2l2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 83619]
- **Diseases:** metabolic disorders (MESH:D008659), fibrosis (MESH:D005355), MASLD (MESH:D008107), liver steatosis (MESH:D005234), NAFLD (MESH:D065626)
- **Chemicals:** THC (MESH:D013759), endocannabinoid (MESH:D063388), sucrose (MESH:D013395), CBD (-), fatty acid (MESH:D005227), cannabinoids (MESH:D002186), lipid (MESH:D008055)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13008911/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13008911/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC13008911/full.md

---
Source: https://tomesphere.com/paper/PMC13008911